3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells

American Journal of Cancer Research

Volumn 5, Issue 9, 2015, Pages 2673-2685

  Liu, Zhe ^a   Sun, Yiming ^a   Hong, Haiyu ^b   Zhao, Surong ^a   Zou, Xue ^a   Ma, Renqiang ^b   Jiang, Chenchen ^c   Wang, Zhiwei ^a,d   Li, Huabin ^b   Liu, Hao ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

3 BrPA.; Breast cancer.; DNR.; MCT1

Indexed keywords

3 BROMOPYRUVATE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; MONOCARBOXYLATE TRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MCF 7 CELL LINE; MDA MB 231; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR MODEL; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 85006210407     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ponisovskiy MR. Warburg effect mechanism as the target for theoretical substantiation of a new potential cancer treatment. Crit Rev Eukaryot Gene Expr 2011; 21: 13-28.
2. Bayley JP and Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012; 24: 62-67.
3. Koppenol WH, Bounds PL and Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
4. Sotgia F, Martinez-Outschoorn UE and Lisanti MP. Genetic induction of the Warburg effect inhibits tumor growth. Oncotarget 2012; 3: 1266-1267.
5. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T and Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis 2014; 35: 2203-2213.
6. Joyce H, McCann A, Clynes M and Larkin A. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Exp Opin Drug Metab Toxicol 2015; 11: 795-809.
7. Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 2015; 18: 1-17.
8. Pavan B, Paganetto G, Rossi D and Dalpiaz A. Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discov Today 2014; 19: 1563-1571.
9. Zhang YK, Wang YJ, Gupta P and Chen ZS. Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS J 2015; 17: 802-812.
10. Choi YH and Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014; 20: 793-807.
11. Meng X, Liao S, Wang X, Wang S, Zhao X, Jia P, Pei W and Zheng X. Reversing P-glycoproteinmediated multidrug resistance in vitro by alpha- asarone and beta-asarone, bioactive cistrans isomers from Acorus tatarinowii. Biotechnol Lett 2014; 36: 685-691.
12. Piecuch A and Oblak E. Yeast ABC proteins involved in multidrug resistance. Cell Mol Biol Lett 2014; 19: 1-22.
13. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R and Den Boer ML. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113: 2014-2021.
14. Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA and Ito S. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol Pharmacol 2013; 83: 377-388.
15. Xiao H, Li S, Zhang D, Liu T, Yu M and Wang F. Separate and concurrent use of 2-deoxy-Dglucose and 3-bromopyruvate in pancreatic cancer cells. Oncol Rep 2013; 29: 329-334.
16. Gonzalez CD, Alvarez S, Ropolo A, Rosenzvit C, Bagnes MF and Vaccaro MI. Autophagy, Warburg, and Warburg reverse effects in human cancer. Biomed Res Int 2014; 2014: 926729.
17. Dylag M, Lis P, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A and Ulaszewski S. 3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun 2013; 434: 322-327.
18. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C and Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-326.
19. Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A and Ulaszewski S. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J Bioenerg Biomembr 2012; 44: 155-161.
20. Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr 2012; 44: 1-6.
21. Shoshan MC. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr 2012; 44: 7-15.
22. Ganapathy-Kanniappan S, Kunjithapatham R and Geschwind JF. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 2013; 33: 13-20.
23. El Sayed SM, Mahmoud AA, El Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, Hashim MS, Hemdan SB, Kadry ZM, Abdelmoaty MA, Gabr AG, Omran FM, Nabo MM and Ahmed NS. Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses 2013; 81: 866-870.
24. Falasca M and Linton KJ. Investigational ABC transporter inhibitors. Expert Opin Invest Drugs 2012; 21: 657-666.
25. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, Peterson TR, Carette JE, Brummelkamp TR, Clish CB and Sabatini DM. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013; 45: 104-108.
26. Kartal-Yandim M, Adan-Gokbulut A and Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol 2015; 1-11.
27. Tomasetti C. Drug resistance. Adv Exp Med Biol 2014; 844: 303-316.
28. Granchi C and Minutolo F. Anticancer agents that counteract tumor glycolysis. ChemMed- Chem 2012; 7: 1318-1350.
29. Lee ZW, Teo XY, Tay EY, Tan CH, Hagen T, Moore PK and Deng LW. Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance. Br J Pharmacol 2014; 171: 4322-4336.
30. Oshikata A, Matsushita T and Ueoka R. Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng 2011; 111: 590- 593.
31. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K and Fujiwara Y. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006; 99: 9-17.
32. Kovalev AA, Tsvetaeva DA and Grudinskaja TV. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol 2013; 35: 287-290.
33. Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH and Haluska P. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther 2011; 10: 117-125.
34. Nambaru PK, Hubner T, Kock K, Mews S, Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C, Rosskopf D, Kowalczyk DW, Kroemer HK, Weiss FU, Mayerle J, Lerch MM and Ritter CA. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos 2011; 39: 132- 139.
35. Pelicano H, Martin DS, Xu RH and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
36. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT and Galina A. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 2009; 417: 717-726.
37. Cardaci S, Desideri E and Ciriolo MR. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr 2012; 44: 17-29.
38. Modok S, Mellor HR and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006; 6: 350- 354.
39. Holland KA and Holland IB. Adventures with ABC-proteins: highly conserved ATP-dependent transporters. Acta Microbiol Immunol Hung 2005; 52: 309-322.
40. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ and Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-621.
41. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP and Pouyssegur J. CD147 subunit of lactate/ H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 2011; 108: 16663-16668.